(BFM Bourse) – The biotech specializing in the analysis of genome modifications and cellular health is experiencing a strong surge on the stock market after announcing the launch of its FiberSmart solution.
While the Parisian market is evolving almost at a standstill at the start of the afternoon, Genomic Vision stands out. The biotech title jumped 62% around 4:30 p.m., a significant increase even though the low nominal of the title (0.041 euros) favors major stock market shifts.
The stock market boom for the tricolor biotech specializing in the study of structural and dynamic changes in DNA, particularly in the human genome, comes after the announcement of the launch of FiberSmart.
This software based on artificial intelligence aims to automate the detection and quantification of fluorescent signals on combed DNA molecules, that is to say deposited on slides to be visualized and analyzed.
Tested by AstraZeneca
This software must make it possible to visualize and analyze “the kinetics of DNA replication [le mouvement par lequel l’ADN est synthétisé, NDLR] up to three times more accurately and up to ten times faster than existing Genomic Vision software solutions.
This technology has been successfully tested and validated by the Swedish-British pharmaceutical group AstraZeneca and the Fritz Lipmann Institute, named after the 1953 Nobel laureate in medicine, in Germany.
This software is compatible with FiverVision and FiverVision-S, Genomic Vision’s molecular combing platform.
Many applications
“Our proprietary DNA combing technology has multiple potential applications, particularly in the field of cell and gene therapy, where a very precise analysis of replication parameters is essential to understand the mechanisms of action of new innovative therapies. “, underlines the CEO of Genomic Vision, quoted in a press release.
“With the launch of this software, we are making it easier for users to harness the full potential of our proprietary advanced genomic analysis technology,” he added.
At the end of last month, the company had indicated that its cash position stood at 760,000 euros at the end of December. The group nevertheless believes that it has the necessary financing to ensure its development over the next twelve months. Genomic Vision still has 26.88 million of the 28.8 million euros in an OCABSA financing line set up in May.
This method of financing, which combines bonds convertible into shares (OCA) with share subscription warrants (BSA), allows companies that are fragile and excluded from the credit market to quickly find fresh money to ensure their operation. Nevertheless, this process is generally accompanied by a high dilution for the shareholders because the financial intermediary who subscribes to these securities then has the task of selling the shares obtained on the market. The Autorité des marchés financiers (AMF) has repeatedly issued warnings about the risks associated with these instruments
Julien Marion – ©2023 BFM Bourse
Are you following this action?
Receive all the information about GENOMIC VISION in real time: